Press Releases

Date Title and Summary Additional Formats
Toggle Summary Zynerba Pharmaceuticals Announces New FAB-C Phase 2 Open-Label Data in Patients with Fragile X Syndrome
- Significant Improvements in Behavioral Symptoms Observed in Patients and Sustained through 38 Weeks of Treatment with ZYN002 - - Presentation Today at the 16 th NFXF International Fragile X Conference - FAB-C Week 38 - Extension Phase Data: ADAMS Mean Percent Improvement From Baseline FAB-C Week
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Oral Presentation of ZYN002 Data at the 16th NFXF International Fragile X Conference in July 2018
DEVON, Pa. , April 23, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Positive Meeting with U.S. Food and Drug Administration and Plans to Conduct a Single Pivotal Study of ZYN002 in Fragile X Syndrome to Support an NDA Filing
Company Expects to Initiate Pivotal Study Mid-Year 2018 and Deliver Top-line Data in 2019 DEVON, Pa. , March 05, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Poster Presentation at the 2018 Annual Meeting of the American Academy of Neurology (AAN)
DEVON, Pa. , March 22, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Pricing of Public Offering of Common Stock
DEVON, Pa. , July 20, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) today announced the pricing of an underwritten public offering of 4,062,500 shares of its common stock at a price of $8.00 per share, for a gross deal size of $32.5 million , before deducting underwriting
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Proposed Public Offering of Common Stock
DEVON, Pa. , July 19, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering.  All of the shares to be sold in the offering will be offered by
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Publication of Preclinical Data in Neuropsychopharmacology Demonstrating Effect of Cannabidiol Gel Treatment in Reduction of Relapse in an Addiction Model
Results show effect of transdermally-delivered cannabidiol (ZYN002) in an animal model of drug relapse and extend its therapeutic potential to relapse prevention in substance use disorders DEVON, Pa. , March 26, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc.
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Sustained Improvements in Emotional and Behavioral Symptoms of Fragile X Syndrome through 12 Months of Treatment with ZYN002
- Patients Experienced a 77% Improvement in Aberrant Behaviors Associated with Social Avoidance Compared to Baseline after One Year of ZYN002 Treatment - FAB0C Month 12: ADAMS Percent Improvement from Baseline with ZYN002 FAB-C Month 12: ABC-CFXS Percent Improvement from Baseline with ZYN002 -
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Top Line Results from ZYN001 THC-Prodrug Patch Phase 1 Study
DEVON, Pa. , July 05, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, announced top line results from a Phase 1 clinical program studying
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Twelve Month ZYN002 Data from STAR 2 Study in Patients with Focal Seizures at the 2018 Annual Meeting of the American Academy of Neurology (AAN)
Continued Improvement in Seizure Control Seen in Adult Refractory Focal Seizure Patients Receiving ZYN002 through 12 Months of Open Label Exposure Median Change in Seizure Rates at Months 3, 6, 9 and 12: All ZYN002-treated patients in STAR 2 Median Change in Seizure Rates at Months 3, 6, 9 and 12:
View HTML
Toggle Summary Zynerba Pharmaceuticals Appoints John P. Butler to Board of Directors
DEVON, Pa. , April 16, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare
View HTML
Toggle Summary Zynerba Pharmaceuticals Initiates CONNECT-FX, a Pivotal Clinical Trial of ZYN002 in Fragile X Syndrome
Study will Evaluate the Efficacy and Safety of Transdermally-Delivered Cannabidiol (CBD) in Children and Adolescents with Fragile X Syndrome Top Line Results Expected in Second Half of 2019 Zynerba to host conference call and webcast today at 8:30 am DEVON, Pa.
View HTML
Toggle Summary Zynerba Pharmaceuticals Initiates Open-Label Phase 2 Trial of ZYN002 in Developmental and Epileptic Encephalopathies (DEE)
DEVON, Pa. , April 10, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare
View HTML
Toggle Summary Zynerba Pharmaceuticals Provides 2018 Clinical and Corporate Update
 - Focusing Strategy on Rare and Near-Rare Neurological and Psychiatric Disorders - - Pediatric Neurologist Liza Squires, M.D. Joins as Chief Medical Officer - - Conference Call to be Held at 8:30 AM Tomorrow , January 4, 2018 - DEVON, Pa. , Jan. 03, 2018 (GLOBE NEWSWIRE) --   Zynerba
View HTML
Toggle Summary Zynerba Pharmaceuticals Provides Clinical Update and Announces Two New Clinical Indications
- Company Will Focus on Four Childhood Neuropsychiatric Disorders: FXS, DEE, Autism Spectrum Disorder and 22q11.2 Deletion Syndrome - - Cash Runway Now Extends into the Second Half of 2020 - - Conference Call to be Held Today at 8:30 am Eastern Time - DEVON, Pa. , Dec.
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports First Quarter 2018 Financial Results and Operational Highlights
DEVON, Pa. , May 08, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Operational Highlights
DEVON, Pa. , March 12, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights
Zynerba to host conference call and webcast today at 8:30 am DEVON, Pa. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights
DEVON, Pa. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the third quarter ended September
View HTML
Toggle Summary Zynerba Pharmaceuticals to Host Conference Call to Provide Second Quarter 2018 Business Update
DEVON, Pa. , July 31, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, will host a conference call at 8:30 am EDT on Thursday August 2, 2018
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the 2018 BIO Investor Forum
DEVON, Pa. , Oct. 11, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido , Zynerba’s Chief Executive Officer,
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference
DEVON, Pa. , Nov. 20, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the 38th Annual Canaccord Genuity Growth Conference
DEVON, Pa. , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Financial Officer, Jim Fickenscher
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the Cantor Global Healthcare Conference
DEVON, Pa. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the H.C. Wainwright 20th Annual Global Investment Conference
DEVON, Pa. , Aug. 31, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
DEVON, Pa. , May 31, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the Oppenheimer 28th Annual Healthcare Conference
DEVON, Pa. , March 14, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare
View HTML